Healthtech startup CureMeAbroad has raised $1.1 million in a pre-seed funding round led by healthcare-focused venture capital fund SteerX Ventures, with existing investor AIRA also participating.
Advertisment
The startup said the fresh capital will be used to expand its network of accredited hospitals, enter new patient source markets and strengthen its AI-powered technology. It also plans to build its operations and technology teams.
CureMeAbroad is also looking to expand its treatment offerings into non-elective specialties, including orthopaedics and oncology, and is exploring physical experience centres in key international markets.
The latest funding follows a $600,000 pre-seed round announced in April 2026, which included backing from Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, Vikrant Potnis and AIRA Buildon.
What does CureMeAbroad do?
Founded in June 2025 by Aditya Oza and Mikhail Bohra, Pune-headquartered CureMeAbroad helps patients seeking treatment overseas find and compare hospitals and arrange their care.
Its platform allows patients to check healthcare providers against Joint Commission International, or JCI, accreditation or equivalent national standards, obtain treatment estimates and book care. It also provides support during the treatment journey.
CureMeAbroad’s platform combines healthcare discovery, treatment planning, pricing transparency and patient assistance.
CureMeAbroad currently attracts more than 22,500 visitors a month and operates a hospital network spanning six countries. In September, Global Healthcare Accreditation, or GHA, awarded CureMeAbroad its Medical Travel Facilitator Certification.
GHA said the company’s network includes more than 400 accredited hospital partners across six countries and supports patients from their initial search and comparison of treatment options through to treatment and post-treatment follow-up.
The accreditation body also said CureMeAbroad primarily serves patients from Western markets, including the US, UK, Australia and Canada.
Plans to expand the platform
CureMeAbroad said the new funding will allow it to enter additional patient source markets while expanding its existing hospital network.
“SteerX didn’t need convincing that this category needs an AI-native platform,” Oza said.
The startup has also identified orthopaedics and oncology as areas for expansion as it moves further into non-elective treatments.
Lalit Singla, founder and CEO of SteerX Ventures, said cost pressures and delays in some healthcare systems were contributing to interest in treatment abroad.
“High healthcare costs and long waiting periods are encouraging patients in markets such as the US, Europe and Australia to explore quality care across borders,” Singla said.
He added that CureMeAbroad was developing technology and infrastructure aimed at making the cross-border healthcare process more trusted and seamless.
Targeting $100 million in annual treatment bookings
CureMeAbroad is targeting $100 million in annual patient treatment bookings by FY2028, compared with what it said is a current run rate of $4.8 million.
Its key patient source markets currently include the US, UK, Australia and Canada.
The funding comes as CureMeAbroad seeks to build a broader platform around the different stages involved in arranging treatment overseas, from finding and comparing healthcare providers to estimating costs, booking treatment and receiving support during the process.
SteerX Ventures focuses on early-stage healthcare companies, investing from pre-seed through Series A. Its investment areas include healthcare delivery, diagnostics and treatment, digital health and AI, medical devices, biotechnology and healthcare fintech.